Resolution Bioscience, a part of Agilent, is pioneering next generation cancer diagnostics that enable physicians to tailor treatments for each patient using only a blood test — a liquid biopsy. Our proprietary molecular analytics platform interrogates cell-free DNA for actionable information that, until now, has only been accessible through invasive biopsy procedures. We have developed over 50 focused panels and are currently working on companion diagnostics to support therapeutic approvals. We are dedicated to improving cancer outcomes through a suite of clinical tests to guide selection of targeted therapies and monitor their effectiveness over time.